LEVOFLOXACIN

Levofloxacin Adverse Events Reported to the FDA Over Time

How are Levofloxacin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Levofloxacin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Levofloxacin is flagged as the suspect drug causing the adverse event.

Most Common Levofloxacin Adverse Events Reported to the FDA

What are the most common Levofloxacin adverse events reported to the FDA?

Drug Interaction	204 (1.39%)
Pyrexia	185 (1.26%)
Tendon Rupture	174 (1.18%)
Arthralgia	172 (1.17%)
Tendonitis	158 (1.07%)
Dyspnoea	156 (1.06%)
Diarrhoea	150 (1.02%)
Renal Failure Acute	147 (1%)
Nausea	141 (.96%)
Pneumonia	126 (.86%)
Pain In Extremity	121 (.82%)
	Show More
Vomiting	115 (.78%)
Rash	111 (.75%)
Hypoglycaemia	105 (.71%)
Toxic Epidermal Necrolysis	104 (.71%)
Dizziness	100 (.68%)
Interstitial Lung Disease	97 (.66%)
Myalgia	97 (.66%)
Asthenia	96 (.65%)
Confusional State	92 (.62%)
Pain	91 (.62%)
Tendon Disorder	89 (.6%)
Convulsion	87 (.59%)
Oedema Peripheral	86 (.58%)
Pruritus	83 (.56%)
Tendon Pain	82 (.56%)
Rhabdomyolysis	80 (.54%)
Metabolic Acidosis	79 (.54%)
Hypotension	76 (.52%)
Urticaria	73 (.5%)
Death	71 (.48%)
International Normalised Ratio Incr...	71 (.48%)
Drug Ineffective	69 (.47%)
Thrombocytopenia	69 (.47%)
Electrocardiogram Qt Prolonged	66 (.45%)
Gait Disturbance	66 (.45%)
Liver Disorder	66 (.45%)
Delirium	65 (.44%)
Malaise	65 (.44%)
Renal Failure	64 (.43%)
Back Pain	63 (.43%)
Erythema	63 (.43%)
Loss Of Consciousness	62 (.42%)
Alanine Aminotransferase Increased	61 (.41%)
Anaemia	61 (.41%)
Drug Rash With Eosinophilia And Sys...	61 (.41%)
Fatigue	60 (.41%)
Hepatic Function Abnormal	58 (.39%)
Respiratory Failure	58 (.39%)
Blood Creatinine Increased	57 (.39%)
Condition Aggravated	57 (.39%)
Drug Eruption	57 (.39%)
Insomnia	57 (.39%)
Sepsis	57 (.39%)
Aspartate Aminotransferase Increase...	55 (.37%)
Disorientation	54 (.37%)
Platelet Count Decreased	53 (.36%)
Headache	52 (.35%)
Decreased Appetite	51 (.35%)
Muscular Weakness	51 (.35%)
Rotator Cuff Syndrome	51 (.35%)
Acute Respiratory Distress Syndrome	50 (.34%)
Cough	49 (.33%)
Dehydration	49 (.33%)
Anaphylactic Shock	48 (.33%)
Paraesthesia	48 (.33%)
Tremor	48 (.33%)
Clostridium Difficile Colitis	47 (.32%)
Tachycardia	47 (.32%)
Musculoskeletal Pain	46 (.31%)
Myocardial Infarction	45 (.31%)
Multi-organ Failure	44 (.3%)
Stevens-johnson Syndrome	43 (.29%)
Clostridial Infection	42 (.29%)
Haemoglobin Decreased	42 (.29%)
Septic Shock	42 (.29%)
Abdominal Pain	41 (.28%)
Blood Pressure Decreased	41 (.28%)
Shock	41 (.28%)
Cardiac Arrest	40 (.27%)
Chills	40 (.27%)
Drug Hypersensitivity	40 (.27%)
Hepatotoxicity	40 (.27%)
Joint Swelling	40 (.27%)
Pancytopenia	40 (.27%)
Fall	39 (.26%)
Hypersensitivity	39 (.26%)
Renal Impairment	39 (.26%)
White Blood Cell Count Decreased	39 (.26%)
Abasia	38 (.26%)
Altered State Of Consciousness	38 (.26%)
Blood Bilirubin Increased	38 (.26%)
Cholestasis	37 (.25%)
Urinary Tract Infection	37 (.25%)
Coma	36 (.24%)
Hypoaesthesia	36 (.24%)
Rash Generalised	36 (.24%)
Depressed Level Of Consciousness	35 (.24%)
Respiratory Distress	35 (.24%)
Torsade De Pointes	35 (.24%)
Disseminated Intravascular Coagulat...	34 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Levofloxacin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Levofloxacin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Levofloxacin

What are the most common Levofloxacin adverse events reported to the FDA?

Epidermal And Dermal Conditions	945 (6.42%)
Neurological	657 (4.46%)
Infections - Pathogen Unspecified	590 (4.01%)
Respiratory	503 (3.42%)
Hepatic And Hepatobiliary	431 (2.93%)
Gastrointestinal Signs	424 (2.88%)
Joint	353 (2.4%)
Tendon, Ligament And Cartilage	347 (2.36%)
Hematology Investigations	337 (2.29%)
Injuries	335 (2.27%)
Therapeutic And Nontherapeutic Effe...	334 (2.27%)
	Show More
Renal Disorders	320 (2.17%)
Musculoskeletal And Connective Tiss...	319 (2.17%)
Muscle	318 (2.16%)
Bacterial Infectious	291 (1.98%)
Cardiac Arrhythmias	291 (1.98%)
Lower Respiratory Tract Disorders	233 (1.58%)
Hepatobiliary	224 (1.52%)
Cardiac And Vascular Investigations	222 (1.51%)
Gastrointestinal Motility And Defec...	216 (1.47%)
Deliria	211 (1.43%)
Body Temperature Conditions	199 (1.35%)
Allergic Conditions	178 (1.21%)
White Blood Cell	168 (1.14%)
Seizures	156 (1.06%)
Movement Disorders	150 (1.02%)
Anemias Nonhemolytic And Marrow Dep...	132 (.9%)
Decreased And Nonspecific Blood Pre...	130 (.88%)
Electrolyte And Fluid Balance Condi...	122 (.83%)
Glucose Metabolism Disorders	117 (.79%)
Renal And Urinary Tract Investigati...	114 (.77%)
Urinary Tract Signs	94 (.64%)
Angiedema And Urticaria	93 (.63%)
Central Nervous System Vascular	93 (.63%)
Acid-base	92 (.62%)
Ocular Infections, Irritations And ...	90 (.61%)
Fatal Outcomes	87 (.59%)
Oral Soft Tissue Conditions	87 (.59%)
Platelet	86 (.58%)
Enzyme	85 (.58%)
Appetite And General Nutritional	80 (.54%)
Metabolic, Nutritional And Blood Ga...	80 (.54%)
Medication Errors	79 (.54%)
Encephalopathies	78 (.53%)
Vision	77 (.52%)
Bone And Joint Injuries	76 (.52%)
Sleep Disorders	75 (.51%)
Coronary Artery	74 (.5%)
Fungal Infectious	72 (.49%)
Physical Examination Topics	72 (.49%)
Lifestyle Issues	71 (.48%)
Skin Vascular Abnormalities	68 (.46%)
Water, Electrolyte And Mineral	64 (.43%)
Anxiety Disorders	62 (.42%)
Upper Respiratory Tract Disorders	61 (.41%)
Mental Impairment	58 (.39%)
Coagulopathies And Bleeding Diathes...	57 (.39%)
Headaches	57 (.39%)
Cardiac Disorder Signs	56 (.38%)
Gastrointestinal Hemorrhages	55 (.37%)
Bronchial Disorders	51 (.35%)
Disturbances In Thinking	51 (.35%)
Pleural	51 (.35%)
Protein And Chemistry Analyses	50 (.34%)
Vascular Hemorrhagic	50 (.34%)
Gastrointestinal Inflammatory Condi...	49 (.33%)
Heart Failures	49 (.33%)
Depressed Mood Disorders	48 (.33%)
Myocardial	48 (.33%)
Nephropathies	48 (.33%)
Psychiatric	47 (.32%)
Viral Infectious	45 (.31%)
Vascular	44 (.3%)
Gastrointestinal Ulceration And Per...	43 (.29%)
Microbiology And Serology	38 (.26%)
Peripheral Neuropathies	36 (.24%)
Bone, Calcium, Magnesium And Phosph...	35 (.24%)
Pericardial	33 (.22%)
Therapeutic Procedures And Supporti...	33 (.22%)
Hematological And Lymphoid Tissue T...	32 (.22%)
Skin And Subcutaneous Tissue	32 (.22%)
Eye	31 (.21%)
Procedural And Device Related Injur...	31 (.21%)
Skin Appendage Conditions	31 (.21%)
Hearing	30 (.2%)
Arteriosclerosis, Stenosis, Vascula...	29 (.2%)
Chemical Injury And Poisoning	28 (.19%)
Cranial Nerve Disorders	28 (.19%)
Vulvovaginal Disorders	28 (.19%)
Peritoneal And Retroperitoneal Cond...	27 (.18%)
Changes In Physical Activity	26 (.18%)
Pulmonary Vascular	26 (.18%)
Tongue Conditions	25 (.17%)
Vascular Hypertensive	25 (.17%)
Suicidal And Self-injurious Behavio...	24 (.16%)
Hemolyses And Related Conditions	23 (.16%)
Product Quality Issues	23 (.16%)
Administration Site Reactions	22 (.15%)
Inner Ear And Viiith Cranial Nerve	22 (.15%)
Embolism And Thrombosis	21 (.14%)
Ocular Neuromuscular	20 (.14%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Levofloxacin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Levofloxacin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.